Indoco Remedies posted lower than expected numbers for 4QFY2017. In sales, the company posted revenues of `266cr (`311cr expected) v/s. `255cr in 4QFY2016, growth of 4.2% yoy. The formulation business posted sales of `251.6cr, up 3.3% yoy, while API at `12.0cr was down 4.7% yoy. The domestic formulation at `130.1cr recorded a yoy de-growth of 2.2%. On EBITDA front, the company posted an EBITDA of 8.0% (17.6% expected) v/s. 12.7% in 4QFY2016. The dip came in on the back of the high R&D expenses, which came in at 5.2% of sales v/s. 7.4% of sales in 4QFY2016. Consequently, PAT came in at `18cr (lower than expectations) v/s. `39cr in 4QFY2016, de-growth of 14.4% yoy. On the back of valuations, we maintain our SELL on the stock, on back of low profitability.
Download Full Report View Full Report in BrowserPlease Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...